MARLBOROUGH, Mass., May 16, 2023 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced a new partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.
Ringo is a two-time national champion from the University of Georgia who was recently drafted by the Philadelphia Eagles. The launch of the partnership with Hologic is timed with Mother's Day and National Women's Health Week (May 14-20, 2023).
Hale's story is a familiar one: a woman who did not prioritize her preventive care screenings as she focused on managing her family, career and other commitments. As a single mother, she was diagnosed with breast cancer just days after Ringo began his freshman year in college. She is now cancer-free after completing treatment, but Ringo and Hale know how lucky they are and want to encourage women not to delay annual screenings.
"Kelee and Tralee's story resonates with all of us because we have heard from women — time and again — who have prioritized their families and other responsibilities while putting their own health screenings on the back burner," said Erik Anderson, Hologic's Division President of Breast and Skeletal Health Solutions. "We couldn't be more grateful that they are sharing their personal story as a way to reach women about the critical importance of annual breast cancer screenings and making their health a priority."
Hologic, a pioneer in 3D mammography and creator of the Genius® 3D Mammography™ exam, is committed to increasing awareness about the life-saving power of annual mammograms and other routine health screenings. The partnership with Ringo and Hale will further that impact through media interviews, public appearances and digital content.
Media Contact
Gina Kent
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$71.65 |
Daily Change: | 0.89 1.26 |
Daily Volume: | 7,640,910 |
Market Cap: | US$16.260B |
December 18, 2024 December 09, 2024 December 02, 2024 November 04, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB